For instance, CAIX has been demonstrated as a suitable target for selective chimeric antigen receptor (CAR) T cell therapy with a cure rate of 20% and without any systemic side effects in an In vivo glioma xenograft mouse model [168]. Here, CA9 is linked to glioma.